Metaproterenol hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: Metaproterenol hydrochloride
• 英文别名: Rac-Metaproterenol HCl；5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;hydrochloride
• 化学式: C₁₁H₁₇NO₃*ClH
• 分子量: 247.722
• InChiKey: IGPZZIRRNVCAFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.55
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72.7
• 氢给体数：
  5
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  metaproterenol bitartrate 在 sodium carbonate 、 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 生成 Metaproterenol hydrochloride
  参考文献：
  名称：

  Metaproterenol, Isoproterenol, and Their Bisdimethylcarbamate Derivatives as Human Cholinesterase Inhibitors

  摘要：

  Metaproterenol and isoproterenol are bronchodilators that provide a structural basis for many other bronchodilators currently in use. One of these structurally related bronchodilators is terbutaline; it is administered as a prodrug, bambuterol, and is metabolized (bioconverted) into terbutaline by butyrylcholinesterase (BChE). The metabolism rate can be affected by BChE gene polymorphism in the human population and BChE stereoselectivity. The aim of our study was to investigate inhibition of human BChE and acetylcholinesterase (AChE) with metaproterenol, isoproterenol, and newly synthesized racemic bisdimethylcarbamate derivatives of metaproterenol (metacarb) and isoproterenol (isocarb) and their (R)-enantiomers to see if their bioconversion is affected by BChE inhibition in the same way as that for bambuterol. Metacarb and isocarb proved to be selective BChE inhibitors, as they progressively inhibited AChE 960 to 80 times more slowly than BChE(UU). All studied cholinesterases displayed poor affinity for metaproterenol and isoproterenol, yet BChE(UU) had an affinity about five times higher than that of AChE.

  DOI：

  10.1021/jm300289k

文献信息

• Skin penetration system for salts of amine-functional drugs
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0351897A2

  公开（公告）日：1990-01-24

  The invention involves pharmaceutical compositions for topical application comprising: (a) a pharmaceutically-acceptable salt of addition of an amine-functional drug (other than opioid analgesic drugs); (b) a C₇ to C₂₂ straight-chain or branched-chain, saturated or unsaturated, fatty acid having a melting point of less than about 50°C; and (c) a C₃-C₄ alkane diol.

  本发明涉及用于局部应用的药物组合物，包括 (a) 一种胺功能药物（阿片类镇痛药除外）的药学上可接受的加成盐； (b) C₇ 至 C₂₂ 直链或支链、饱和或不饱和脂肪酸，熔点低于约 50°C；以及 (c) C₃-C₄ 烷二醇。
• Combination of a beta-2 adrenoceptor agonist and an aminosugar and their use for the treatment of immunomodulatory disorders
  申请人：Astion Development A/S

  公开号：EP1642574A2

  公开（公告）日：2006-04-05

  The invention relates to combinations of an aminosugar and a beta-2 adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensitivity and inflammation, in particular hypersensitivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

  本发明涉及一种氨基糖和β-2肾上腺素受体激动剂（如沙丁胺醇）的组合，用于治疗与超敏性和炎症有关的疾病，特别是超敏性皮肤病。氨基糖最好是单糖衍生物。
• Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
  申请人：Weidner Sloth Morten

  公开号：US20050130935A1

  公开（公告）日：2005-06-16

  The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensivity and inflamation, in particular hypersensivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

  本发明涉及一种氨基糖和β-2-肾上腺素受体激动剂（如沙丁胺醇）的组合，用于治疗与过敏和炎症有关的疾病，特别是过敏性皮肤病。氨基糖最好是单糖衍生物。
• COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS
  申请人：Astion Development A/S

  公开号：EP1496917B1

  公开（公告）日：2005-12-07